3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
2
Neoplasms
1
Lung Neoplasms
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
cediranib
×
Clear all
NCT00777153
2016-12-28
REGAL
AstraZeneca
Phase 3
Completed
423 enrolled
13 charts